StockData
Jupiter Neurosciences, Inc. logo

Jupiter Neurosciences, Inc. (JUNS) stock

JUNSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 0/30
$1.52−0.18 (-10.59%)

Close on Nov 17, 2026Market cap $1.17MP/E –Yield –

Jupiter Neurosciences r&d expenses

Research and development expenses are spending on new products and technology.

Jupiter Neurosciences's R&D Expenses for the twelve months ending Jun 30, 2026 was $1.87M, up 23.2% year over year. For fiscal 2025 it was $2.09M, up 323.5% from the year before.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$2.09M+323.5%
FY2024Dec 31, 2024$492.66K-48.4%
FY2023Dec 31, 2023$954.79K–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$600.35K-20.9%
Q1 FY2026Mar 31, 2026$411.05K-11.9%
Q4 FY2025Dec 31, 2025$43.68K-78.3%
Q3 FY2025Sep 30, 2025$816.70K+788.6%
Q2 FY2025Jun 30, 2025$759.45K+651.4%
Q1 FY2025Mar 31, 2025$466.75K+373.1%
Q4 FY2024Dec 31, 2024$201.01K-17.9%
Q3 FY2024Sep 30, 2024$91.91K-61.6%
Q2 FY2024Jun 30, 2024$101.08K–
Q1 FY2024Mar 31, 2024$98.67K–
Q4 FY2023Dec 31, 2023$244.73K–
Q3 FY2023Sep 30, 2023$239.46K–

More Jupiter Neurosciences figures

See a number that looks wrong?